Table 1.

Patient characteristics.

Variable	n = 670
Age (years), mean (SD)	68.1 (6.9)
PSA level (ng/mL), median (IQR)	12.7 (7.2–24.3)
cT stage	cT1: 110 cT2a: 132, cT2b: 91, cT2c: 37 cT3a: 239, cT3b: 61
Gleason score	3 + 3: 22 3 + 4: 93, 4 + 3: 103 4 + 4: 135, 3 + 5: 25 4 + 5: 255, 5 + 4: 34 5 + 5: 3
%PC (%), median (IQR)	41.7 (25.0–60.0)
ADT duration (months), median (IQR)	25.0 (24.0–27.0)
CIRT dose	63 Gy(RBE)/20 fr: 77 57.6Gy(RBE)/16 fr: 298 51.6 Gy(RBE)/12 fr: 295
Early BCR	36 (5.4%)
Time to early BCR (months), median (IQR)	42.8 (29.0–45.3)

ADT: androgen deprivation therapy, BCR: biochemical recurrence, CIRT: carbon-ion radiotherapy, IQR: interquartile range, %PC: percentage of positive biopsy cores, PSA: prostate-specific antigen, SD: standard deviation.